Use of pcsk9 inhibitor for reducing cardiovascular risk

ES3072854T3Active Publication Date: 2026-07-06SANOFI BIOTECH SAS +1
0 Cites 0 Cited by

Patent Information

Application Number
ES2019715280T
Authority / Receiving Office
ES · ES
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-03-04
Filing Date
2019-03-06
Publication Date
2026-07-06
Estimated Expiration
2039-03-06

AI Technical Summary

Technical Problem

Despite modern therapies, cardiovascular events occur frequently in high-risk patients post-acute coronary syndrome, with significant residual risk due to inadequate lipid lowering by current drugs, leading to high mortality and morbidity.

Method used

Administration of a PCSK9 antibody or its antigen-binding fragment with specific CDR sequences for at least three years to patients with elevated LDL-C levels post-acute coronary syndrome, despite maximally tolerated statin therapy, to reduce major adverse cardiovascular events.

Benefits of technology

Reduces the risk of mortality and major cardiovascular events by 15-35% and increases survival time, specifically targeting high-risk patients with conditions like diabetes and polyvascular disease.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention provides methods for treating diseases and disorders associated with elevated lipid and lipoprotein levels. These methods consist of administering a pharmaceutical composition containing a PCSK9 inhibitor to a patient at high cardiovascular risk. In certain formulations, the PCSK9 inhibitor is an anti-PCSK9 antibody, such as the example antibody designated mAb316P or alirocumab. The methods of the present invention are useful for treating patients at high cardiovascular risk who have hypercholesterolemia and elevated levels of other atherogenic lipoproteins that are not adequately controlled with the maximum tolerated dose of statins.In particular, the methods of the present invention are useful for reducing cardiovascular risk and decreasing atherogenic lipoproteins in patients with high cardiovascular risk during the 12 months following an acute coronary syndrome event, despite treatment with the maximum tolerated dose of statins.
Need to check novelty before this filing date? Find Prior Art